Real-World data shows High-Dose tafamidis may slow nerve damage in ATTR-CM patients
NCT ID NCT06393465
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 27 times
Summary
This study looked at how well a high dose of the drug tafamidis (61 mg daily) slows nerve damage in people with a heart condition called ATTR-CM. Researchers reviewed medical records of 50 patients who had already taken the drug for at least a year. The goal was to see if the drug slowed the worsening of nerve problems in real-world settings, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.